genentech inc u s sales seen as flat overall demand strong genentech inc expects first quarter u s product sales to be "essentially flat" with fourth quarter levels suggesting a leveling off in rapid growth but it said overall product demand remains strong the south san francisco calif biotechnology company also said a small trial of its cancer drug avastin in people with a form of lung cancer was halted because at least two people developed a disorder related to the digestive and respiratory systems and one of them died genentech posted u s product sales of &# billion for the fourth quarter with royalties and other revenue added total fourth quarter revenue was &# billion genentech didnt provide a forecast for overall first quarter revenue avastin is approved to treat colorectal cancer and nonsmall cell lung cancer the avastin trial that was halted was testing the drug in combination with chemotherapy and radiation therapy in people with small cell lung cancer 
